Persistent Idiopathic Facial Pain

Back

Background

Persistent idiopathic facial pain (PIFP), originally known as atypical facial pain, refers to pain along the territory of the trigeminal nerve that does not fit the classic presentation of other cranial neuralgias.[1, 2] The pain is usually of long duration, lasting most of the day (if not continuous), is unilateral, and is without autonomic signs or symptoms. It is described as a severe ache, crushing sensation, or burning sensation. Upon examination and workup, no abnormality is noted.

Within the group of chronic facial pain syndromes, PIFP represents a particular diagnostic challenge. Patients frequently are misdiagnosed or attribute their pain to a prior event, such as a dental procedure or facial trauma. Psychiatric symptoms of depression and anxiety are prevalent in this population, further compounding the diagnostic conundrum. Treatment of PIFP is typically less effective than that of other facial pain syndromes, and a multidisciplinary approach is required to address the many facets of this pain syndrome.

For patient education resources, see the Brain and Nervous System Center, as well as Trigeminal Neuralgia (Facial Nerve Pain).

Pathophysiology and Etiology

The Headache Classification Subcommittee of the International Headache Society defines PIFP as follows[3] :

PIFP usually does not have a specific cause; however, injury of the trigeminal nerve proximally or distally may lead to this disorder. Demyelination, either central or peripheral, may initiate PIFP symptoms. Infectious causes should also be considered.

Epidemiology and Prognosis

Because of a lack of agreement on classification criteria, accurate figures on the frequency of PIFP are difficult to obtain. The estimated incidence has been estimated to be 1 case per 100,000 population (0.001%), though this number may be an underestimate.[4] A German study that included 3336 participants estimated the lifetime prevalence of PIFP to be 0.03%.[5]

PIFP mainly affects adults and is rare in children.[4] Overall, the disorder affects both sexes approximately equally, but more women than men seek medical care.[4]

For patients who do not respond to the available pharmacologic and nonpharmacologic therapies, the prognosis is poor.

History

Persistent idiopathic facial pain (PIFP) is essentially a diagnosis of exclusion. Daily or near-daily headaches are a widespread problem in clinical practice.[1, 4] According to population-based data from the United States, Europe, and Asia, chronic daily headache affects a large number of patients (approximately 4-5% of the population).[4, 6, 7]

A careful history and physical examination, including a dental consultation, laboratory studies, and imaging studies, may be necessary to rule out occult pathology. Underlying pathology such as malignancy, vasculitis, infection, and central or peripheral demyelination may manifest early as neuralgia, and not until focal neurologic deficits, imaging abnormalities, or laboratory abnormalities are discovered does the diagnosis become evident. Rare cases of referred pain must also be considered.

It is important to distinguish PIFP from other chronic daily headache syndromes, including the following[4, 6, 7, 8, 9, 10] :

The following are characteristic of other chronic facial pain syndromes from which PIFP should be differentiated.

Clinical features distinguishing other chronic facial pain syndromes from PIFP

Trigeminal neuralgia

Trigeminal neuralgia is characterized by severe bursts of lancinating pain in 1 or more branches of the trigeminal nerve. Bursts are quick, repetitive, electric shock–like sensations. Each pain episode is seconds in duration, occurs irregularly, and is not related to the patient’s pulse. Treatments include antiepileptic drugs (AEDs), antidepressants (eg, tricyclic antidepressants [TCAs], selective serotonin reuptake inhibitors [SSRIs], and norepinephrine reuptake inhibitors [NeRIs]), injections, and surgical intervention.[11, 12]

Postherpetic neuralgia

Postherpetic neuralgia is defined as pain that persists for 1-6 months after an acute herpes zoster infection. The pain is neuropathic in nature. It is associated with allodynia and hyperalgesia, most commonly affecting the V1 distribution of the trigeminal nerve. The mainstays of treatment are AEDs, TCAs, and SSRIs.[13]

Temporomandibular joint syndrome

TMJ syndrome is characterized by focal tenderness to one or both TMJs and is usually aggravated by chewing, talking, and jaw movement. The quality of the pain is similar to that of PIFP (ie, dull, aching, crushing, or burning). Treatment of TMJ syndrome is often directed either at the articular joint itself or at fatigue of the periodontal ligament and the temporalis.

Cluster headache

Cluster headache is characterized by the sudden onset of severe, boring, and burning pain. Episodes last 30-180 minutes. The pain awakens the patient from sleep and does not improve with rest. Many individuals pace, and some may even injure themselves because of the severity of the pain. Associated symptoms include ipsilateral conjunctival injection, tearing, and nasal congestion. The male-to-female ratio is 6:1.

Abortive treatment includes oxygen (8-15 L), sumatriptan injections, dihydroergotamine, or combinations thereof. Preventive treatment includes verapamil, lithium, divalproex sodium, and topiramate.[14]

Cluster-tic syndrome

Cluster-tic syndrome is a difficult diagnosis and is easily confused with other facial pain syndromes. The 3 types of pain include pain with clusterlike features, pain with trigeminal neuralgia features, and a combination of these 2 types. Treatment includes AEDs, TCAs, and SSRIs or NeRIs.[15]

SUNCT syndrome

SUNCT syndrome may be a variation of the cluster-tic syndrome. It is characterized by brief (15-120 seconds) bursts of pain in the eyes, temple, or face. The pain is usually unilateral and is described as burning, stabbing, or electric. It occurs frequently (>100 episodes) in a 24-hour period. Neck movements can trigger the pain. SUNCT syndrome is refractory to medical therapy.[16]

Jabs and jolts syndrome, primary stabbing headache, or icepick headache

In this setting, head pain occurs as a single stab or a series of stabs. The pain is exclusive to or predominantly felt in the distribution of V1. Stabs last for up to a few seconds and recur with an irregular frequency that ranges from once daily to many times a day. No other accompanying symptoms are noted, and the pain cannot be attributed to another disorder. This syndrome is refractory to medical treatment.[17]

Raeder syndrome

Raeder syndrome is characterized by a V1 distribution of a unilateral burning facial pain associated with hyperesthesia, ptosis, and miosis. The pain may be caused by trauma, a middle cranial fossa mass lesion, syphilis, or sinusitis. In the absence of these underlying conditions, the pain is self-limited.[18]

Thalamic pain syndrome

Thalamic pain syndrome is described as unilateral facial pain and dysesthesias and is attributed to a lesion of the ventral-medial thalamic nuclei. It is typically a severe, burning, or aching pain localized to the contralateral side of the face. The diagnosis can be made by means of imaging studies or can be based on the presence of other associated symptoms in the trunk or limbs.

Hemicrania continua

The rare condition known as hemicrania continua is characterized by unilateral headache and facial pain. The daily head pain is continuous (24 h/d, 7 d/wk), with pain exacerbation periods that occur with variable frequency (from multiple times per week to every third month or even less often). The pain at baseline is mild to moderate, and exacerbations are moderate to severe in intensity. It is associated with migraine or cluster features (eg, photophobia, nausea, aura, lacrimation, eye injection).

Hemicrania continua responds to indomethacin, and this response facilitates diagnosis.[14, 19, 20] Abortive treatment includes oxygen (8-15 L), sumatriptan injections, and dihydroergotamine. Preventive treatment includes verapamil, lithium, divalproex sodium, and topiramate.[14]

Migraine

Migraine is a common condition. The female-to-male ratio is 3:1. It is commonly unilateral but can be bilateral. The pain has a throbbing quality and feels as if it is associated with a pulse. Photophobia, phonophobia, and osmophobia are typical features, as is nausea. The pain worsens with exertion and improves with sleep. The patient may or may not experience aura.

Pharmacologic therapy includes abortive and preventive medications, depending on the frequency and severity of the headaches. Abortive agents include serotonin agonists, ergotamine, isometheptene, and anti-inflammatory drugs. Preventive agents include AEDs, beta-blockers, calcium channel blockers, TCAs, SSRIs or NeRIs, and angiotensin-receptor blockers.

Physical Examination

As indicated by the definition of PIFP, the findings from the general physical examination and the neurologic examination should be normal.

Pain evoked responses after stimulation are less common with PIFP than with trigeminal neuralgia. Palpation- and manipulation-induced tenderness of the TMJ is associated more closely with TMJ syndrome and less so with other cephalalgias or facial pain syndromes.

Approach Considerations

Persistent idiopathic facial pain (PIFP) is a diagnosis of exclusion. All other causes of facial pain (see Presentation) must be excluded (especially those amenable to surgical treatment).

Diagnostic imaging may be helpful. Magnetic resonance imaging (MRI) of the brain, with and without gadolinium contrast, is the modality of choice in this setting. Computed tomography (CT) of the brain with contrast has a lower yield than MRI does because it yields poorer resolution of the posterior fossa and cranial nerves.

Approach Considerations

Medical treatment of persistent idiopathic facial pain (PIFP) is usually less satisfactory than medical treatment of other facial pain syndromes. Pharmacotherapeutic knowledge is paramount in the treatment of this refractory pain syndrome. A multimechanistic approach, using modulation of both ascending and descending pain pathways, is frequently necessary. The goal of therapy is to manage the pain effectively while giving rise to the fewest possible adverse medication effects.

Anticonvulsants (antiepileptic drugs [AEDs]) and antidepressants (eg, tricyclic antidepressants [TCAs], selective serotonin reuptake inhibitors [SSRIs], and norepinephrine reuptake inhibitors [NeRIs]) are the mainstays of pharmacologic treatment. Narcotics may be appropriate if administered under careful supervision.

Pharmacologic Therapy

Medications used to treat PIFP include the following:

Of these classes of medications, anticonvulsants and antidepressants appear to be the most effective.[21] The neuropathic component of the pain responds well to anticonvulsants and antidepressants.

Surgical, Psychiatric, and Alternative Treatments

Details of neurosurgical interventions to treat PIFP are beyond the scope of this review. If analgesic surgery is under consideration, it should be performed at a center well versed in such procedures. Occipital nerve block, though useful for treating several craniofacial neuralgias, does not appear to be especially effective against PIFP.[22, 23]

Psychiatric treatment is important in the overall management of a patient with chronic pain.

The results of a small study from Taiwan suggest that low-energy (eg, 800-nm wavelength) diode laser therapy may prove to be a useful alternative treatment for PIFP.[24]

Alternative therapies such as acupuncture and neuromuscular reeducation have been tried and should be considered as part of a comprehensive treatment plan. Available data on alternative treatments are limited.[25, 26]

Consultations

Psychometric testing may be of benefit in the evaluation and treatment of patients with headache and facial pain. Many tests have been applied, but probably the most widely used is the Minnesota Multiple Personality Inventory (MMPI). Although psychometric testing is especially useful in the evaluation of the chronic headache and facial pain patients, a thorough discussion of such testing is beyond the scope of this discussion and is mentioned here only for completeness.

Consultation with a dentist may be of benefit.

All treatments should be provided in cooperation with the patient’s primary care physician.

Medication Summary

The goal of therapy is to manage the persistent facial pain with anticonvulsants and antidepressants. Narcotics may be appropriate if administered under careful supervision.

Amitriptyline

Clinical Context:  Amitriptyline increases the synaptic concentration of serotonin or norepinephrine in the central nervous system (CNS) by inhibiting their reuptake by the presynaptic neuronal membrane. It is useful as an analgesic for certain types of chronic and neuropathic pain.

Nortriptyline (Pamelor)

Clinical Context:  Nortriptyline has demonstrated effectiveness in the treatment of chronic pain. It increases the synaptic concentration of serotonin or norepinephrine in the CNS by inhibiting their reuptake by the presynaptic neuronal membrane. Additional pharmacodynamic effects, such as desensitization of adenyl cyclase and downregulation of beta-adrenergic receptors and serotonin receptors, appear to play roles.

Duloxetine (Cymbalta)

Clinical Context:  Duloxetine is approved by the US Food and Drug Administration (FDA) for diabetic peripheral neuropathic pain. It is a potent inhibitor of neuronal serotonin and norepinephrine reuptake.

Class Summary

Tricyclic antidepressants (TCAs) are a complex group of drugs that have central and peripheral anticholinergic effects and sedative effects. They block the active reuptake of norepinephrine and serotonin.

Carbamazepine (Tegretol, Carbatrol, Epitol)

Clinical Context:  Carbamazepine has antineuralgic effects. It may depress the activity of the nucleus ventralis of the thalamus or may decrease synaptic transmission or summation of temporal stimulation, thus leading to neural discharge by limiting the influx of sodium ions across the cell membrane or through other unknown mechanisms. The target blood serum concentration range is 4-12 mg/L.

Pregabalin (Lyrica)

Clinical Context:  Pregabalin is FDA-approved for use in postherpetic neuralgia and painful diabetic peripheral neuropathy. Compared with placebo, it brings about a statistically significant reduction in mean pain score and pain-related sleep interference.

Pregabalin binds with high affinity to the alpha2-delta subunit of voltage-gaited calcium channels, thereby reducing excitatory neurotransmitters. It has a half-life of about 6 hours and is eliminated via renal excretion. A decrease in creatinine clearance results in decreased elimination and, therefore, a higher plasma concentration. Peak plasma concentration occurs at 1 and 1.5 hours after oral intake. Bioavailability is 90%. After repeated dosing, steady-state concentration is achieved at 24-48 hours. The drug can be taken with or without food.

Gabapentin (Neurontin, Gralise)

Clinical Context:  Gabapentin has properties common to other anticonvulsants and exerts antineuralgic effects. Its exact mechanism of action is not known. Gabapentin is structurally related to gamma-aminobutyric acid (GABA) but does not interact with GABA receptors. It has efficacy at the alpha2-delta subunit.

Phenytoin (Dilantin, Phenytek)

Clinical Context:  Phenytoin may stabilize neuronal membranes and treat neuralgia by increasing efflux or decreasing influx of sodium ions across cell membranes in the motor cortex during generation of nerve impulses. When the serum level is in or near the therapeutic range, adjust the dose in 30- to 50-mg increments. Small increments may cause greater than expected increases in serum concentration (ie, Michaelis-Menten drug kinetics). Because half-life is concentration-dependent, steady-state serum levels may take as long as 3 weeks to develop.

Lamotrigine (Lamictal)

Clinical Context:  Lamotrigine is a triazine derivative that is useful in the treatment of neuralgia. It inhibits the release of glutamate and inhibits voltage-sensitive sodium channels (thus stabilizing the neuronal membrane). For dose adjustments, follow the manufacturer's recommendations.

Topiramate (Topamax)

Clinical Context:  Topiramate's precise mechanism of action is unknown, but the following properties may contribute to its efficacy:

• Blockage of voltage-dependent sodium channels, as demonstrated by electrophysiologic and biochemical evidence

• Augmentation of GABA activity at some GABA-A receptor subtypes

• Antagonism of the AMPA/kainate subtype of the glutamate receptor

• Inhibition of carbonic anhydrase, particularly isozymes II and IV

Valproic acid (Depacon, Depakene, Stavzor)

Clinical Context:  The activity of valproic acid may be related to increased brain levels of GABA or enhanced GABA action.

Divalproex sodium (Depakote, Depakote ER)

Clinical Context:  The activity of divalproex sodium may be related to increased brain levels of GABA or enhanced GABA action.

Class Summary

Although anticonvulsants are useful for neuropathic pain, their mechanism of action in this setting is unknown.

Lidocaine anesthetic (Topicaine, Lido Patch, Lidoderm 5% patch)

Clinical Context:  Several studies support topical administration of lidocaine as treatment of postherpetic neuralgia. In a placebo-controlled study, lidocaine gel (5%) yielded significant relief in 23 patients studied. Lidocaine tape also decreases the severity of pain.

Capsaicin topical (Dolorac, Capsin, Zostrix)

Clinical Context:  Capsaicin is a natural chemical derived from plants of the Solanaceae family. By depleting and preventing reaccumulation of substance P in peripheral sensory neurons, capsaicin may render treated areas insensitive to pain. Substance P is thought to be a chemomediator of pain transmission from the periphery to the CNS.

Class Summary

Analgesics may aid in decreasing the severity of pain.

Dronabinol

Clinical Context:  Dronabinol is an orally active cannabinoid receptor agonist with complex effects on the CNS, including central sympathomimetic activity. Cannabinoid receptors have been discovered in neural tissues. These receptors play a role in mediating the effects of dronabinol and other cannabinoids. Dronabinol undergoes extensive first-pass hepatic metabolism by microsomal hydroxylation, yielding both active and inactive metabolites. It has also been shown to be highly plasma protein bound.

Several studies have shown dronabinol to have modest effects in treating neuropathic pain and muscle spasticity in individuals with demyelinating disease states.

Class Summary

Drugs of the cannabinoid class may aid in reducing neuropathic pain.

What is persistent idiopathic facial pain (PIFP)?How is persistent idiopathic facial pain (PIFP) defined?What is the prevalence of persistent idiopathic facial pain (PIFP)?Which patient groups have the highest prevalence of persistent idiopathic facial pain (PIFP)?What is the prognosis of persistent idiopathic facial pain (PIFP)?What is the focus of clinical history to evaluate for persistent idiopathic facial pain (PIFP)?How is persistent idiopathic facial pain (PIFP) differentiated from trigeminal neuralgia?How is persistent idiopathic facial pain (PIFP) differentiated from postherpetic neuralgia?How is persistent idiopathic facial pain (PIFP) differentiated from temporomandibular joint (TMJ) syndrome?How is persistent idiopathic facial pain (PIFP) differentiated from cluster headache?How is persistent idiopathic facial pain (PIFP) differentiated from cluster-tic syndrome?How is persistent idiopathic facial pain (PIFP) differentiated from SUNCT syndrome?How is persistent idiopathic facial pain (PIFP) differentiated from icepick headache?How is persistent idiopathic facial pain (PIFP) differentiated from Raeder syndrome?How is persistent idiopathic facial pain (PIFP) differentiated from thalamic pain syndrome?How is persistent idiopathic facial pain (PIFP) differentiated from hemicrania continua?How is persistent idiopathic facial pain (PIFP) differentiated from migraine?Which physical findings are characteristic of persistent idiopathic facial pain (PIFP)?Which conditions are included in the differential diagnoses of persistent idiopathic facial pain (PIFP)?What are the differential diagnoses for Persistent Idiopathic Facial Pain?How is persistent idiopathic facial pain (PIFP) diagnosed?How is persistent idiopathic facial pain (PIFP) treated?Which medications are used in the treatment of persistent idiopathic facial pain (PIFP)?What is the role of neurosurgery in the treatment of persistent idiopathic facial pain (PIFP)?How is pain managed in persistent idiopathic facial pain (PIFP)?What is the role of acupuncture and neuromuscular reeducation in the treatment of persistent idiopathic facial pain (PIFP)?Which specialist consultations are beneficial to patients with persistent idiopathic facial pain (PIFP)?What is the role of medications in the treatment of persistent idiopathic facial pain (PIFP)?Which medications in the drug class Antiemetic Agents are used in the treatment of Persistent Idiopathic Facial Pain?Which medications in the drug class Anesthetics, Topical are used in the treatment of Persistent Idiopathic Facial Pain?Which medications in the drug class Anticonvulsants are used in the treatment of Persistent Idiopathic Facial Pain?Which medications in the drug class Antidepressants, TCAs are used in the treatment of Persistent Idiopathic Facial Pain?

Author

Stanley J Krolczyk, DO, RPh, Associate Professor, Director of Multiple Sclerosis Center, Department of Neurology, University of South Florida College of Medicine

Disclosure: Received grant/research funds from TEVA for clinical trials; Received consulting fee from TEVA for speaking and teaching; Received consulting fee from EMD SERONO for speaking and teaching; Received consulting fee from BIOGEN for speaking and teaching; Received grant/research funds from EMD SERONO for clinical trials; Received consulting fee from Novartis for speaking and teaching; Received grant/research funds from NOVARTIS for clinical trials.

Coauthor(s)

Kavita Kalidas, MD, Assistant Professor, Department of Neurology, University of South Florida College of Medicine

Disclosure: Nothing to disclose.

Martin A Myers, MD, University of South Florida College of Medicine

Disclosure: Nothing to disclose.

Chief Editor

Robert A Egan, MD, NW Neuro-Ophthalmology

Disclosure: Received honoraria from Biogen Idec and Genentech for participation on Advisory Boards.

Acknowledgements

Joseph Carcione Jr, DO, MBA Consultant in Neurology and Medical Acupuncture, Medical Management and Organizational Consulting, Central Westchester Neuromuscular Care, PC; Medical Director, Oxford Health Plans

Joseph Carcione Jr, DO, MBA is a member of the following medical societies: American Academy of Neurology

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Salary Employment

References

  1. Pascual J, Colas R, Castillo J. Epidemiology of chronic daily headache. Curr Pain Headache Rep. 2001 Dec. 5(6):529-36. [View Abstract]
  2. Zakrzewska JM. Multi-dimensionality of chronic pain of the oral cavity and face. J Headache Pain. 2013 Apr 25. 14(1):37. [View Abstract]
  3. Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders: 2nd edition. Cephalalgia. 2004. 24 Suppl 1:9-160. [View Abstract]
  4. Kavuk I, Yavuz A, Cetindere U, Agelink MW, Diener HC. Epidemiology of chronic daily headache. Eur J Med Res. 2003 Jun 30. 8(6):236-40. [View Abstract]
  5. Mueller D, Obermann M, Yoon MS, Poitz F, Hansen N, Slomke MA, et al. Prevalence of trigeminal neuralgia and persistent idiopathic facial pain: a population-based study. Cephalalgia. 2011 Nov. 31(15):1542-8. [View Abstract]
  6. Bordini C, Antonaci F, Stovner LJ, Schrader H, Sjaastad O. "Hemicrania continua": a clinical review. Headache. 1991 Jan. 31(1):20-6. [View Abstract]
  7. Madland G, Feinmann C. Chronic facial pain: a multidisciplinary problem. J Neurol Neurosurg Psychiatry. 2001 Dec. 71(6):716-9. [View Abstract]
  8. Volcy M, Rapoport AM, Tepper SJ, Sheftell FD, Bigal ME. Persistent idiopathic facial pain responsive to topiramate. Cephalalgia. 2006 Apr. 26(4):489-91. [View Abstract]
  9. Kaup AO, Mathew NT, Levyman C, Kailasam J, Meadors LA, Villarreal SS. Side locked' migraine and trigeminal autonomic cephalgias: evidence for clinical overlap. Cephalalgia. 2003 Feb. 23(1):43-9. [View Abstract]
  10. Leone M, D'Amico D, Frediani F, Torri W, Sjaastad O, Bussone G. Clinical considerations on side-locked unilaterality in long-lasting primary headaches. Headache. 1993 Jul-Aug. 33(7):381-4. [View Abstract]
  11. Turp JC, Gobetti JP. Trigeminal neuralgia versus atypical facial pain. A review of the literature and case report. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1996 Apr. 81(4):424-32. [View Abstract]
  12. Maarbjerg S, Sørensen MT, Gozalov A, Bendtsen L, Olesen J. Field-testing of the ICHD-3 beta diagnostic criteria for classical trigeminal neuralgia. Cephalalgia. 2014 Jul 22. [View Abstract]
  13. Cunningham AL, Dworkin RH. The management of post-herpetic neuralgia. BMJ. 2000 Sep 30. 321(7264):778-9. [View Abstract]
  14. Rozen TD. Trigeminal Autonomic Cephalgias. Continuum. 2006 Dec. 12:170-93.
  15. Watson P, Evans R. Cluster-tic syndrome. Headache. 1985 May. 25(3):123-6. [View Abstract]
  16. Pareja JA, Sjaastad O. SUNCT syndrome. A clinical review. Headache. 1997 Apr. 37(4):195-202. [View Abstract]
  17. Pareja JA, Ruiz J, de Isla C, al-Sabbah H, Espejo J. Idiopathic stabbing headache (jabs and jolts syndrome). Cephalalgia. 1996 Apr. 16(2):93-6. [View Abstract]
  18. Mokri B. Raeder's paratrigeminal syndrome. Original concept and subsequent deviations. Arch Neurol. 1982 Jul. 39(7):395-9. [View Abstract]
  19. Kuritzky A. Indomethacin-resistant hemicrania continua. Cephalalgia. 1992 Feb. 12(1):57-9. [View Abstract]
  20. Peres MF, Silberstein SD, Nahmias S, et al. Hemicrania continua is not that rare. Neurology. 2001 Sep 25. 57(6):948-51. [View Abstract]
  21. Cornelissen P, van Kleef M, Mekhail N, Day M, van Zundert J. Evidence-based interventional pain medicine according to clinical diagnoses. 3. Persistent idiopathic facial pain. Pain Pract. 2009 Nov-Dec. 9(6):443-8. [View Abstract]
  22. Jürgens TP, Müller P, Seedorf H, Regelsberger J, May A. Occipital nerve block is effective in craniofacial neuralgias but not in idiopathic persistent facial pain. J Headache Pain. 2012 Apr. 13(3):199-213. [View Abstract]
  23. Vorenkamp KE. Interventional procedures for facial pain. Curr Pain Headache Rep. 2013 Jan. 17(1):308. [View Abstract]
  24. Yang HW, Huang YF. Treatment of persistent idiopathic facial pain (PIFP) with a low-level energy diode laser. Photomed Laser Surg. 2011 Oct. 29(10):707-10. [View Abstract]
  25. Ogutcen-Toller M, Uzun E, Incesu L. Clinical and magnetic resonance imaging evaluation of facial pain. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2004 May. 97(5):652-8. [View Abstract]
  26. Rozen TD. Antiepileptic drugs in the management of cluster headache and trigeminal neuralgia. Headache. 2001 Nov-Dec. 41 Suppl 1:S25-32. [View Abstract]